Skip to main content
. 2018 Dec;10(12):6677–6694. doi: 10.21037/jtd.2018.11.87

Figure 4.

Figure 4

Pairwise comparisons: median OS HR and median of median OS. carbo, carboplatin; cetux, cetuximab; cis, cisplatin; doc, docetaxel; gem, gemcitabine; HR, hazard ratio; nab-tax, nab-paclitaxel; neci, necitumumab; OS, overall survival; tax, paclitaxel; vin, vinorelbine.